PURPOSE: Common Variable Immunodeficiency Disorder (CVID) is a complex disorder that predisposes patients to recurrent and severe infections. The C104R mutation in the transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) is the most frequent mutation identified in patients with CVID. We carried out a detailed immunological and molecular study in a family with a C104R mutation. METHODS: We have undertaken segregation analysis of a kindred with C104R mutations of the TACI gene. Detailed immunological and molecular investigations were carried out for this kindred and the clinical phenotype was compared to the genotype. RESULTS: Segregation analysis of our kindred showed that inheriting single or double copy of the C104R mutation does not consign an individual to CVID. All heterozygotes in the family were phenotypically different, ranging from asymptomatic to ill-health. A family member with a wild type TACI variant had CVID-related phenotype including IgA deficiency and type 1 diabetes. Interestingly, a family member with the homozygous C104R/C104R variant did not meet the criteria for CVID because he had excellent, albeit unsustained, vaccine responses to T cell dependent and T cell independent vaccine antigens despite profound hypogammaglobulinemia. CONCLUSION: The C104R mutation does not correlate with the clinical phenotypes in this family.
PURPOSE: Common Variable Immunodeficiency Disorder (CVID) is a complex disorder that predisposes patients to recurrent and severe infections. The C104R mutation in the transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) is the most frequent mutation identified in patients with CVID. We carried out a detailed immunological and molecular study in a family with a C104R mutation. METHODS: We have undertaken segregation analysis of a kindred with C104R mutations of the TACI gene. Detailed immunological and molecular investigations were carried out for this kindred and the clinical phenotype was compared to the genotype. RESULTS: Segregation analysis of our kindred showed that inheriting single or double copy of the C104R mutation does not consign an individual to CVID. All heterozygotes in the family were phenotypically different, ranging from asymptomatic to ill-health. A family member with a wild type TACI variant had CVID-related phenotype including IgA deficiency and type 1 diabetes. Interestingly, a family member with the homozygous C104R/C104R variant did not meet the criteria for CVID because he had excellent, albeit unsustained, vaccine responses to T cell dependent and T cell independent vaccine antigens despite profound hypogammaglobulinemia. CONCLUSION: The C104R mutation does not correlate with the clinical phenotypes in this family.
Authors: Menno C van Zelm; Julie Smet; Brigitte Adams; Françoise Mascart; Liliane Schandené; Françoise Janssen; Alina Ferster; Chiung-Chi Kuo; Shoshana Levy; Jacques J M van Dongen; Mirjam van der Burg Journal: J Clin Invest Date: 2010-03-08 Impact factor: 14.808
Authors: Menno C van Zelm; Ismail Reisli; Mirjam van der Burg; Diana Castaño; Carel J M van Noesel; Maarten J D van Tol; Cristina Woellner; Bodo Grimbacher; Pablo J Patiño; Jacques J M van Dongen; José L Franco Journal: N Engl J Med Date: 2006-05-04 Impact factor: 91.245
Authors: J E Volanakis; Z B Zhu; F M Schaffer; K J Macon; J Palermos; B O Barger; R Go; R D Campbell; H W Schroeder; M D Cooper Journal: J Clin Invest Date: 1992-06 Impact factor: 14.808
Authors: A E J Poodt; G J A Driessen; A de Klein; J J M van Dongen; M van der Burg; E de Vries Journal: Clin Exp Immunol Date: 2008-12-11 Impact factor: 4.330
Authors: Rohan Ameratunga; Klaus Lehnert; See-Tarn Woon; David Gillis; Vanessa L Bryant; Charlotte A Slade; Richard Steele Journal: Clin Rev Allergy Immunol Date: 2018-04 Impact factor: 8.667
Authors: Shoichiro Tsuji; Lucas Stein; Nobuhiko Kamada; Gabriel Nuñez; Richard Bram; Bruce A Vallance; Ana E Sousa; Jeffrey L Platt; Marilia Cascalho Journal: J Clin Invest Date: 2014-10-01 Impact factor: 14.808
Authors: Rohan Ameratunga; See-Tarn Woon; Vanessa L Bryant; Richard Steele; Charlotte Slade; Euphemia Yee Leung; Klaus Lehnert Journal: Front Immunol Date: 2018-01-26 Impact factor: 7.561
Authors: Rohan Ameratunga; Maia Brewerton; Charlotte Slade; Anthony Jordan; David Gillis; Richard Steele; Wikke Koopmans; See-Tarn Woon Journal: Front Immunol Date: 2014-09-15 Impact factor: 7.561
Authors: Guillem de Valles-Ibáñez; Ana Esteve-Solé; Mònica Piquer; E Azucena González-Navarro; Jessica Hernandez-Rodriguez; Hafid Laayouni; Eva González-Roca; Ana María Plaza-Martin; Ángela Deyà-Martínez; Andrea Martín-Nalda; Mónica Martínez-Gallo; Marina García-Prat; Lucía Del Pino-Molina; Ivón Cuscó; Marta Codina-Solà; Laura Batlle-Masó; Manuel Solís-Moruno; Tomàs Marquès-Bonet; Elena Bosch; Eduardo López-Granados; Juan Ignacio Aróstegui; Pere Soler-Palacín; Roger Colobran; Jordi Yagüe; Laia Alsina; Manel Juan; Ferran Casals Journal: Front Immunol Date: 2018-05-14 Impact factor: 7.561
Authors: Rohan Ameratunga; Wikke Koopmans; See-Tarn Woon; Euphemia Leung; Klaus Lehnert; Charlotte A Slade; Jessica C Tempany; Anselm Enders; Richard Steele; Peter Browett; Philip D Hodgkin; Vanessa L Bryant Journal: Clin Transl Immunology Date: 2017-10-20